Anti-Human CXCL10 (IP-10) (Clone CPTC-CXCL10-1) – Purified No Carrier Protein

VEIIATMK

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0129A-4E4-H3/K3 activity is directed against human CXCL10 peptide VEIIATMK.

CPTC-CXCL10-1

Chemotactic cytokines, along with their GPCR receptors, play important roles in regulating lymphoid tissue development, immune homeostasis, and inflammatory responses by directing leukocyte migration into injured or infected tissues¹. Additionally, chemokine signaling in the tumor microenvironment contributes to tumor cell proliferation, migration, invasion, angiogenesis, evasion, and resistance to immune checkpoint inhibitors.

CXCL10, along with its receptor CXCR3, regulates immune cell migration, differentiation and activation via recruitment of cytotoxic lymphocytes, natural killer (NK) cells, NKT cells, and macrophages². CXCL10 and CXCR3 operate within an axis that includes the selective ligands CXCL9 and CXCL11, which also bind to the CXCR3 receptor. Together the CXCL9, -10, - 11/CXCR3 axis controls the differentiation of naïve T cells to T helper 1 (Th1) cells, Th1 polarization, and migration of immune cells to their focal sites. Additionally, in normal tissue, they attenuate angiogenesis and thereby promote an anti-tumor effect. In cancer, the CXCL9, - 10, -11/CXCR3 axis can be tumorigenic, increasing proliferation and metastasis.

EB0129A-4E4-H3/K3 was generated in rabbit for use in immuno-MRM assays using a synthetic peptide derived from human CXCL10, VEIIATMK³. EB0129A-4E4-H3/K3 can detect CXCL10 by immunohistochemistry, NCI60 protein array, and in Western blotting of cell lysates obtained from HeLa, A549, MCF7 and NCI-H226 cell lines⁴

CXCL10 is secreted by monocytes, endothelial cells, and fibroblasts as well as epithelial cells in thymus tissue. CXCL10 is produced by microglial cells in response to viral stimulation and in cancer cells in response to IFN-γ.

CXCR3

1 Gao SH, Liu SZ, Wang GZ, et al. Life (Basel). 11(12):1282. 2021.
2 Tokunaga R, Zhang W, Naseem M, et al. Cancer Treat Rev. 63:40-47. 2018.
3 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
4 https://antibodies.cancer.gov/detail/CPTC-CXCL10-1#CPTC-CXCL10-1